Immunotherapy of cancer - Generation of CEA specific CTL using CEA peptide pulsed dendritic cells

Advances in Experimental Medicine and Biology

Volumn 417, Issue , 1997, Pages 519-524

  Alters, Susan E ^a   Gadea, Jose R ^a   Philip, Ramila ^a  

^a RPR Gencell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD86 ANTIGEN; HLA A2 ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN PRESENTATION; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030805240     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9966-8_85     Document Type: Article

References (15)

1. Rosenberg, S. A et. al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897 (1987).
2. Rosenberg, S.A. Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol. Today 9, 58-62 (1988).
3. Rosenberg, S.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann. Surg. 210, 474-85 (1989).
4. Thompson, J.A., Gruner, F., and Zimmermann, W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5, 344-366 (1991).
5. Tsang, K. Y., et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Canc. Ins. 87, 982-990 (1995).
6. Inaba, K., Metly, P.J., Crowley, M.T., and Steinman, R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172, 631-640 (1990).
7. + CTLs from naive precursors. J. Immunol. 153, 996-1003(1994).
8. Romani, N., et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
9. + T cell lines from naive precursors. Eur. J. Immunol. 25, 206-1211 (1995).
10. Mayordomo, J.I., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1 (12), 1297-1302 (1995).
11. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287 (1996).
12. Zitvogel, L., et. al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cell, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
13. Ossevoort, M.A., Feltamp, M.C.W., van Veen, K.J.H., Melief, C.J.M., and Kast, W.M. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. 18, 86-94 (1995).
14. Porgador, A., and Gilboa, E. Bone-marrow-generated dendritic cells pulsed with a class 1-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182, 255-260 (1995).
15. Bakker, A. B., et. al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55, 5330-5334 (1995).